SCHEMBL9907348

SCHEMBL9907348

O=C(O)c1ccc2nccc(-c3c(F)cc(Cl)cc3F)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.44
GRM2 Q14416 1/20 0.43
KMO O15229 1/20 0.41
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
HTR5A P47898 2/20 0.40
CDH1 P12830 1/20 0.39
APC P25054 1/20 0.39
CTNNB1 P35222 1/20 0.39
TCF7L2 Q9NQB0 1/20 0.39
TTR P02766 1/20 0.39
ALB P02768 1/20 0.39
MAOA P21397 1/20 0.39
CNR1 P21554 1/20 0.39
DRD1 P21728 1/20 0.39
OPRD1 P41143 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE3A Q14432 1/20 0.39
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108194 0.90 HTR5A (0.48) MAPKAPK2KMOCSNK2A2CSNK2BHTR5A
Formaldehyde SCHEMBL9108251 0.88 HTR5A (0.46) MAPKAPK2KMOCSNK2A2CSNK2BHTR5A
SCHEMBL9907472 0.88 HTR5A (0.44) HTR5AALDH1A1POLBHPGDL3MBTL1
SCHEMBL9907351 0.87 HTR5A (0.42) MAPKAPK2GRM2KMOCSNK2A2CSNK2B
SCHEMBL9907352 0.87 KMO (0.51) MAPKAPK2GRM2KMOCSNK2A2CSNK2B
SCHEMBL9907462 0.86 CSNK2A2 (0.43) MAPKAPK2CSNK2A2CSNK2BHTR5AALDH1A1
SCHEMBL9907387 0.86 MAPKAPK2 (0.45) MAPKAPK2KMOCSNK2A2CSNK2BCDH1
SCHEMBL9907372 0.85 MAPKAPK2 (0.48) MAPKAPK2KMOCSNK2A2CSNK2BCDH1
SCHEMBL9907346 0.85 HTT (0.47) CSNK2A2CSNK2BALDH1A1HPGDL3MBTL1
SCHEMBL9907344 0.85 HTR5A (0.43) MAPKAPK2KMOCSNK2A2CSNK2BHTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E MAPKAPK2 4333/4885GRM2 109/4885KMO 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.